Pieris Pharmaceuticals, Inc. (PIRS)
Largest Insider Buys in Sector
PIRS Stock Price History Chart
PIRS Stock Performance
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Insider Activity of Pieris Pharmaceuticals, Inc.
Over the last 12 months, insiders at Pieris Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Pieris Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Pieris Pharmaceuticals, Inc. have bought $9,380 and sold $2.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $8,500 was made by KIRITSY CHRISTOPHER P (director) on 2023‑05‑25.
List of Insider Buy and Sell Transactions, Pieris Pharmaceuticals, Inc.
| 2023-05-25 | KIRITSY CHRISTOPHER P | director | 10,000 0.0139% | $0.85 | $8,500 | -76.04% | ||
| 2022-05-13 | Demuth Tim | Chief Medical Officer | 6,000 0.0081% | $1.71 | $10,260 | -19.01% | ||
| 2021-08-30 | Sale | Olwill Shane | Chief Development Officer | 38,400 0.0581% | $5.11 | $196,380 | -36.47% | |
| 2020-07-21 | Sale | Aquilo Capital Management, LLC | 10 percent owner | 1.9M 3.4847% | $2.95 | $5.61M | -6.93% | |
| 2019-09-06 | Sale | BVF PARTNERS L P/IL | 10 percent owner | 50,000 0.1024% | $4.50 | $224,970 | -27.75% | |
| 2018-09-14 | KIRITSY CHRISTOPHER P | director | 5,000 0.0095% | $5.11 | $25,525 | -27.05% | ||
| 2018-05-15 | GERAGHTY JAMES A | director | 10,000 0.0185% | $5.75 | $57,500 | -33.22% | ||
| 2018-04-30 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 1M 1.8466% | $6.35 | $6.35M | -31.24% | |
| 2018-02-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 15,794 0.03% | $8.98 | $141,830 | -43.70% | |
| 2018-01-03 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 3.42M 7.0529% | $7.35 | $25.13M | -21.91% | |
| 2017-12-18 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 295,270 0.5963% | $5.70 | $1.68M | +0.35% | |
| 2017-08-17 | Reine Allan | See Remarks | 40,000 0.0952% | $4.89 | $195,600 | +28.08% | ||
| 2017-08-17 | GERAGHTY JAMES A | director | 10,000 0.0235% | $4.82 | $48,200 | +28.08% | ||
| 2017-08-16 | Reine Allan | See Remarks | 90,000 0.2049% | $4.79 | $431,100 | +25.11% | ||
| 2016-06-14 | Matis Louis | SVP, Chief Development Officer | 7,915 0.0202% | $1.71 | $13,535 | +5.18% | ||
| 2016-06-13 | Yoder Stephen S. | President and CEO | 12,000 0.0292% | $1.68 | $20,160 | +1.78% | ||
| 2016-06-13 | DEPTULA-HICKS DARLENE M | SVP, Chief Financial Officer | 5,000 0.012% | $1.66 | $8,300 | +1.78% | ||
| 2016-06-13 | Matis Louis | SVP, Chief Development Officer | 2,085 0.0051% | $1.68 | $3,503 | +1.78% | ||
| 2015-07-06 | ORBIMED ADVISORS LLC | 1M 2.7949% | $2.75 | $2.75M | -23.12% | |||
| 2015-07-06 | Khuong Chau Quang | 1M 2.7949% | $2.75 | $2.75M | -23.12% |
Insider Historical Profitability
| Khuong Chau Quang | 7194222 7.2778% | $8.72 | 1 | 0 | <0.0001% | |
| Aquilo Capital Management, LLC | 10 percent owner | 3675530 3.7182% | $8.72 | 0 | 1 | |
| BVF PARTNERS L P/IL | 10 percent owner | 314139 0.3178% | $8.72 | 0 | 1 | |
| Reine Allan | See Remarks | 65000 0.0658% | $8.72 | 2 | 0 | +26.59% |
| ORBIMED ADVISORS LLC | 10 percent owner | 38870 0.0393% | $8.72 | 1 | 4 | <0.0001% |
| GERAGHTY JAMES A | director | 20000 0.0202% | $8.72 | 2 | 0 | <0.0001% |
| KIRITSY CHRISTOPHER P | director | 20000 0.0202% | $8.72 | 2 | 0 | <0.0001% |
| Matis Louis | SVP, Chief Development Officer | 10000 0.0101% | $8.72 | 2 | 0 | +3.48% |
| Demuth Tim | Chief Medical Officer | 6000 0.0061% | $8.72 | 1 | 0 | <0.0001% |
| Yoder Stephen S. | President and CEO | 6000 0.0061% | $8.72 | 1 | 0 | +1.78% |
| DEPTULA-HICKS DARLENE M | SVP, Chief Financial Officer | 5000 0.0051% | $8.72 | 1 | 0 | +1.78% |
| Olwill Shane | Chief Development Officer | 4638 0.0047% | $8.72 | 0 | 1 |
Institutional Investor Ownership
| Bvf Inc Il | $3.78B | 1561.07 | 20.61M | 0% | +$0 | 27.72 | |
| Lynx1 Capital Management Lp | $1.61B | 664.97 | 8.78M | -10.2% | -$182.59M | 84.78 | |
| Renaissance Technologies | $262,000.00 | 108.28 | 1.43M | +34.23% | +$66,816.61 | <0.0001 | |
| BlackRock | $190.1M | 78.6 | 1.04M | <0.01% | -$19,785.66 | <0.01 | |
| Citadel Advisors LLC | $177.2M | 73.26 | 967,235 | -18.71% | -$40.79M | 0.12 | |
| Acadian Asset Management | $175,000.00 | 72.89 | 962,358 | 0% | +$0 | <0.01 | |
| The Vanguard Group | $166.23M | 68.73 | 907,390 | 0% | +$0 | <0.01 | |
| Geode Capital Management | $141.62M | 58.53 | 772,784 | +1.49% | +$2.08M | 0.01 | |
| Cm Management Llc | $105.34M | 43.55 | 575,000 | -23.33% | -$32.06M | 5.01 | |
| Northern Trust | $44.63M | 18.45 | 243,592 | 0% | +$0 | 0.01 | |
| State Street | $40.82M | 16.88 | 222,819 | 0% | +$0 | <0.01 | |
| Prudential Financial | $40.45M | 16.72 | 220,800 | +100.36% | +$20.26M | 0.06 | |
| Millennium Management LLC | $38.79M | 16.04 | 211,745 | +27.03% | +$8.26M | 0.03 | |
| Squarepoint Ops LLC | $26.72M | 11.05 | 145,833 | New | +$26.72M | 0.1 | |
| Summit Trail Advisors | $25.65M | 10.6 | 140,000 | New | +$25.65M | 0.68 | |
| Citigroup | $16.23M | 6.71 | 88,585 | 0% | +$0 | 0.01 | |
| TWO SIGMA SECURITIES LLC | $10.67M | 4.41 | 58,265 | +277.98% | +$7.85M | 0.24 | |
| UBS | $9.52M | 3.94 | 51,994 | +727.93% | +$8.37M | <0.01 | |
| Tower Research Capital | $7.82M | 3.24 | 42,742 | +426.64% | +$6.34M | 0.08 | |
| Two Sigma Advisers LP | $6.21M | 2.57 | 33,900 | -2.02% | -$128,230.09 | 0.01 | |
| Nj State Employees Deferred Compensation Plan | $5.5M | 2.27 | 30,000 | 0% | +$0 | 0.69 | |
| Raymond James Associates | $5.5M | 2.27 | 30,000 | 0% | +$0 | <0.01 | |
| Group One Trading | $4.71M | 1.95 | 25,700 | +281.87% | +$3.48M | 0.14 | |
| Goldman Sachs | $331,873.00 | 1.72 | 22,638 | +0.02% | +$73.30 | <0.0001 | |
| Xtx Topco Ltd | $3.8M | 1.57 | 20,756 | -47.7% | -$3.47M | 0.21 | |
| Commerce Bank | $3.66M | 1.52 | 20,000 | 0% | +$0 | 0.02 | |
| Kestra Advisory Services LLC | $3,206.00 | 1.33 | 17,500 | 0% | +$0 | <0.0001 | |
| National Asset Management Inc | $5.07M | 1.29 | 17,000 | New | +$5.07M | 0.06 | |
| Hudson Valley Investment Advisors Inc Adv | $2.56M | 1.06 | 14,000 | 0% | +$0 | 0.31 | |
| Cerity Partners | $1.89M | 0.78 | 10,300 | 0% | +$0 | 0.01 | |
| U.S. Bancorp | $1.88M | 0.78 | 10,280 | 0% | +$0 | <0.01 | |
| Morgan Stanley | $1.26M | 0.52 | 6,856 | 0% | +$0 | <0.0001 | |
| Bank of America | $1.13M | 0.47 | 6,145 | +4,137.93% | +$1.1M | <0.0001 | |
| Wells Fargo | $1.02M | 0.42 | 5,573 | +17.05% | +$148,762.25 | <0.0001 | |
| Barclays | $1,000.00 | 0.38 | 5,006 | 0% | +$0 | <0.0001 | |
| Cutler Group Lp | $0 | 0.34 | 4,500 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $365,000.00 | 0.15 | 1,989 | +0.91% | +$3,303.17 | <0.0001 | |
| Truvestments Capital Llc | $205,000.00 | 0.09 | 1,120 | 0% | +$0 | 0.08 | |
| Advisor Group Holdings Inc | $95,000.00 | 0.04 | 516 | 0% | +$0 | <0.0001 | |
| Allworth Financial Lp | $65,000.00 | 0.03 | 350 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $0 | 0.02 | 272 | -52.45% | -$0 | <0.0001 |